465 related articles for article (PubMed ID: 33569740)
21. Silencing TRAIP suppresses cell proliferation and migration/invasion of triple negative breast cancer via RB-E2F signaling and EMT.
Zheng Y; Jia H; Wang P; Liu L; Chen Z; Xing X; Wang J; Tan X; Wang C
Cancer Gene Ther; 2023 Jan; 30(1):74-84. PubMed ID: 36064576
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of SK4 Potassium Channels Suppresses Cell Proliferation, Migration and the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells.
Zhang P; Yang X; Yin Q; Yi J; Shen W; Zhao L; Zhu Z; Liu J
PLoS One; 2016; 11(4):e0154471. PubMed ID: 27124117
[TBL] [Abstract][Full Text] [Related]
23. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
24. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
25. Dihydrotanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells.
Kashyap A; Umar SM; Dev J R A; Prasad CP
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2177-2184. PubMed ID: 34319041
[TBL] [Abstract][Full Text] [Related]
26. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
[TBL] [Abstract][Full Text] [Related]
27. LncRNA T376626 is a promising serum biomarker and promotes proliferation, migration, and invasion via binding to LAMC2 in triple-negative breast cancer.
He Y; Xiao B; Lei T; Xuan J; Zhu Y; Kuang Z; Liu J; He J; Li L; Sun Z
Gene; 2023 Apr; 860():147227. PubMed ID: 36709879
[TBL] [Abstract][Full Text] [Related]
28. Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial-mesenchymal transition in triple-negative breast cancer.
Lv ZD; Yang ZC; Liu XP; Jin LY; Dong Q; Qu HL; Li FN; Kong B; Sun J; Zhao JJ; Wang HB
J Cell Mol Med; 2016 Sep; 20(9):1640-50. PubMed ID: 27027510
[TBL] [Abstract][Full Text] [Related]
29. Transferrin Coated d-penicillamine-Au-Cu Nanocluster PLGA Nanocomposite Reverses Hypoxia-Induced EMT and MDR of Triple-Negative Breast Cancers.
Shome R; Ghosh SS
ACS Appl Bio Mater; 2021 Jun; 4(6):5033-5048. PubMed ID: 35007052
[TBL] [Abstract][Full Text] [Related]
30. GROα overexpression drives cell migration and invasion in triple negative breast cancer cells.
Bhat K; Sarkissyan M; Wu Y; Vadgama JV
Oncol Rep; 2017 Jul; 38(1):21-30. PubMed ID: 28560447
[TBL] [Abstract][Full Text] [Related]
31. FRZB is Regulated by the Transcription Factor EGR1 and Inhibits the Growth and Invasion of Triple-Negative Breast Cancer Cells by Regulating the JAK/STAT3 Pathway.
Liu H; Mei Y; Ma X; Zhang X; Nie W
Clin Breast Cancer; 2022 Oct; 22(7):690-698. PubMed ID: 35787980
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
33. The deubiquitinase BRCC3 increases the stability of ZEB1 and promotes the proliferation and metastasis of triple-negative breast cancer cells.
Huang Q; Zheng S; Gu H; Yang Z; Lu Y; Yu X; Guo G
Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):564-575. PubMed ID: 38449391
[TBL] [Abstract][Full Text] [Related]
34. miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer.
Ji H; Sang M; Liu F; Ai N; Geng C
Pathol Res Pract; 2019 Apr; 215(4):697-704. PubMed ID: 30611621
[TBL] [Abstract][Full Text] [Related]
35. ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells.
Zhang Y; Wang L; Gao P; Sun Z; Li N; Lu Y; Shen J; Sun J; Yang Y; Dai H; Cai H
Int J Mol Med; 2018 Nov; 42(5):2343-2352. PubMed ID: 30226569
[TBL] [Abstract][Full Text] [Related]
36. MiR-212-5p Suppresses the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer by Targeting Prrx2.
Lv ZD; Yang DX; Liu XP; Jin LY; Wang XG; Yang ZC; Liu D; Zhao JJ; Kong B; Li FN; Wang HB
Cell Physiol Biochem; 2017; 44(5):1785-1795. PubMed ID: 29216628
[TBL] [Abstract][Full Text] [Related]
37. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model.
Guo Y; Fan Y; Pei X
Cancer Med; 2020 Apr; 9(7):2564-2578. PubMed ID: 32037729
[TBL] [Abstract][Full Text] [Related]
38. miR-122-5p promotes aggression and epithelial-mesenchymal transition in triple-negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen-activated protein kinase signaling.
Wang Z; Wang X
J Cell Physiol; 2020 Mar; 235(3):2825-2835. PubMed ID: 31541468
[TBL] [Abstract][Full Text] [Related]
39. Extracellular matrix marker LAMC2 targets ZEB1 to promote TNBC malignancy via up-regulating CD44/STAT3 signaling pathway.
Wang D; Keyoumu K; Yu R; Wen D; Jiang H; Liu X; Di X; Zhang S
Mol Med; 2024 May; 30(1):61. PubMed ID: 38760717
[TBL] [Abstract][Full Text] [Related]
40. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]